AdAlta Ltd (1AD):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C7947)
◆英語タイトル:AdAlta Ltd (1AD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7947
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:49
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
AdAlta Ltd (AdAlta), formerly AdAlta Pty Ltd, is a biotechnology company that discovers and develops new class of protein therapeutics for wide range of human diseases. The company’s lead i-body candidate, AD-114, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. Its i-body products are developed using proprietary technology platform that delivers specific biologics and affinity against a variety of therapeutic and diagnostic targets such as cell surface, membrane spanning and complex proteins. AdAlta utilizes the i-body technology to create a pipeline of new drugs for treating fibrotic diseases. The company collaborates with various pharmaceutical and biotech companies in Australia. AdAlta is headquartered in Melbourne, Victoria, Australia.

AdAlta Ltd (1AD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AdAlta Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AdAlta Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
AdAlta Expands Collaboration with The Alfred Hospital 11
AdAlta Enters into Agreement with XL-protein 12
Crossbeta Biosciences Enters Into Agreement With AdAlta For Drug Discovery 13
Licensing Agreements 14
Crossbeta Biosciences Enters into Licensing Agreement with AdAlta 14
Equity Offering 15
AdAlta to Raise Funds through Share Purchase Plan 15
AdAlta Raises USD3.1 Million in Private Placement of Shares 16
AdAlta Raises USD7.5 Million in IPO 17
AdAlta Ltd – Key Competitors 18
AdAlta Ltd – Key Employees 19
AdAlta Ltd – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Financial Announcements 21
Feb 20, 2018: AdAlta: Half year report for the half-year ended 31 December 2017 21
Apr 26, 2017: AdAlta Announces Quarterly Cash Flow Statement 23
Jan 31, 2017: AdAlta: Quarterly Cash Flow Statement 25
Government and Public Interest 27
Jul 25, 2018: AdAlta’s i-body platform: reaching for the high-hanging fruit 27
Jul 24, 2017: AdAlta and La Trobe awarded SIEF Business Fellowship grant to identify novel i-bodies 28
Product News 29
12/07/2017: NHMRC $768,000 Grant for Development of AD-114 in Chronic Kidney Disease 29
11/13/2017: AdAlta to present at Anti-Fibrotic Drug Development Summit in Boston 30
08/21/2017: Compelling new lung disease treatment pioneered in Victoria gains global attention alongside top researchers and drug developers 31
05/08/2017: AdAlta to present eye fibrosis data at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 32
05/01/2017: AdAlta releases Idiopathic Pulmonary Fibrosis Overview Document 33
01/16/2018: Researcher looks to next generation antibody treatment for Chronic Kidney Disease 34
01/08/2018: AdAlta to present at the Biotech Showcase in San Francisco 35
Product Approvals 36
Jan 18, 2017: AdAlta receives Orphan Designation for its lead drug candidate targeting patients with idiopathic pulmonary disease 36
Clinical Trials 37
Apr 18, 2018: AdAlta to advance improved lung fibrosis therapy, AD-214 37
Nov 22, 2017: AdAlta gets commercial-ready after pre-clinical safety studies show promising results 38
Sep 19, 2017: AdAlta announces additional, positive safety data of AD-114 in non-human primates 39
Sep 04, 2017: AdAlta to present kidney fibrosis data at Australian and New Zealand Society of Nephrology Annual Scientific Meeting 40
Jul 18, 2017: AD-114 safe in non-human primates and manufacturing progress update 41
Jan 09, 2017: AdAlta Announces Positive Pre-clinical Data Showing Lead Drug Candidate Has Broad Fibrosis Treatment Potential 43
Other Significant Developments 44
Oct 17, 2018: AdAlta: Quarterly cash flow statement 44
Jul 16, 2018: AdAlta: Quarterly Cash Flow Statement Quarter ended 30 June 2018 46
Jul 27, 2017: AdAlta: Announces Quarterly Cash Flow Statement 47
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
AdAlta Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AdAlta Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AdAlta Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AdAlta Expands Collaboration with The Alfred Hospital 11
AdAlta Enters into Agreement with XL-protein 12
Crossbeta Biosciences Enters Into Agreement With AdAlta For Drug Discovery 13
Crossbeta Biosciences Enters into Licensing Agreement with AdAlta 14
AdAlta to Raise Funds through Share Purchase Plan 15
AdAlta Raises USD3.1 Million in Private Placement of Shares 16
AdAlta Raises USD7.5 Million in IPO 17
AdAlta Ltd, Key Competitors 18
AdAlta Ltd, Key Employees 19

List of Figures
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ AdAlta Ltd (1AD):製薬・医療:M&Aディール及び事業提携情報(AdAlta Ltd (1AD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆